コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nced reactive myeloproliferative response to thrombopoietin.
2 n, soluble transferrin receptor (sCD71), and thrombopoietin.
3 pon stimulation of primary megakaryocytes by thrombopoietin.
4 es, and show altered biochemical response to thrombopoietin.
5 an CD34(+) cells cultured in the presence of thrombopoietin.
6 reduced levels of plasma erythropoietin and thrombopoietin.
7 cktail of stem cell factor, flt3 ligand, and thrombopoietin.
8 ured in the presence of stem cell factor and thrombopoietin.
9 ption factor scl and c-mpl, the receptor for thrombopoietin.
10 unction, and raised serum erythropoietin and thrombopoietin.
11 -6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.
12 cting cytokines kit ligand, flt3 ligand, and thrombopoietin.
13 two doses of 1.2 microg/kg recombinant human thrombopoietin.
14 feration of BaF3/Mpl cells in the absence of thrombopoietin.
15 and controls the proliferative responses to thrombopoietin.
18 ecular and cellular mechanisms through which thrombopoietin affects platelet production provide new i
20 lear cells were incubated in the presence of thrombopoietin and 10% plasma from either ITP patients (
22 expression profiles correlated with that of thrombopoietin and found that genes whose expression ass
23 egulation occurs with the receptors for Epo, thrombopoietin and growth hormone but not with the recep
24 binant hemopoietic growth factors, including thrombopoietin and interkeukin-11, may be useful future
25 e potential of hemopoietic growth factors (, thrombopoietin and interleukin-11) to prevent or treat n
29 ereas megakaryocyte progenitors treated with thrombopoietin and LY294002 showed both a G(1) and a G(2
31 development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopeni
32 gulate the expression of genes such as THPO (thrombopoietin) and ATP5B (ATP synthase, H+ transporting
33 x were reduced, while reticulated platelets, thrombopoietin, and bone marrow megakaryocyte colony-for
35 ure containing IL-3, IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA ov
38 topoietic cell receptors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto
40 tly of the key regulator of megakaryopoiesis thrombopoietin, and may occur during situations of acute
41 n mice by phlebotomy or by administration of thrombopoietin, and ultrastructural analysis was perform
42 h the recent cloning and characterization of thrombopoietin, appreciation of the molecular events sur
44 ifferentiation process driven by the hormone thrombopoietin by which haematopoietic progenitor cells
45 ic progenitor cells, during pre-expansion by thrombopoietin, c-kit ligand, and FLT-3 ligand, on recom
46 ved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise
48 platelet and red blood cell variability, and thrombopoietin/cellular myeloproliferative leukemia viru
49 s harvested from healthy donors treated with thrombopoietin could provide larger increases in platele
50 yocytes may reduce metastasis, we found that thrombopoietin-deficient mice exhibited a 90% relative d
52 rapidly overgrown by a unique population of thrombopoietin-dependent blasts that express immature ma
55 ssful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl wa
57 ation of transforming growth factor-beta1 in thrombopoietin-driven experimental myelofibrosis in mice
60 ne marrow cells grown in liquid culture with thrombopoietin failed to develop polyploid cells greater
62 here that the 2 cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic
65 ys with OP9 stromal cells in the presence of thrombopoietin, IL-6, and IL-11 resulted in the developm
67 rmined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean pla
68 utants and platelets from patients displayed thrombopoietin-independent phosphorylation of signal tra
70 hosphatidylinositol 3-kinase is required for thrombopoietin-induced cell cycling in BaF3/Mpl cells an
71 R-34a expression is also up-regulated during thrombopoietin-induced differentiation of CD34(+) hemato
72 ispensable for megakaryocytopoiesis, and for thrombopoietin-induced ERK1/2 activation in primary mega
73 y increase in A-Raf or B-Raf expression, and thrombopoietin-induced ERK1/2 phosphorylation is similar
74 theless, the absence of Raf-1 does not alter thrombopoietin-induced expansion of primary megakaryocyt
75 from human haematopoietic progenitor cells, thrombopoietin-induced megakaryocytic differentiation le
77 aF3/Mpl cells and megakaryocyte progenitors, thrombopoietin-induced phosphatidylinositol 3-kinase act
79 tors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high
80 tact with hECs and minimal concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-
86 illustrate an involvement for GP Ibalpha in thrombopoietin-mediated events of megakaryocyte prolifer
87 tients, resulting in diminished thrombin and thrombopoietin-mediated integrin alpha(IIb)beta(3) activ
90 unosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improv
91 ponse may also occur with alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA.
92 hGH enhances the effect of a tandem dimer of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis,
93 ed the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or interme
99 tly reported increased in vivo activities of thrombopoietin (Mpl ligand) and leptin following carbohy
100 cluding receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating
101 cture a small upstream open reading frame in thrombopoietin mRNA, and the resulting overproduction of
102 is a loss-of-function variant that promotes thrombopoietin/myeloproliferative leukemia virus oncogen
103 in isolated MKs increased signaling via the thrombopoietin/myeloproliferative leukemia virus oncogen
106 2%) amplification cultures with two (Flt3L + thrombopoietin) or four cytokines (Flt3L + thrombopoieti
107 megakaryocytes in the presence or absence of thrombopoietin, or the development of megakaryocyte DNA
110 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex
112 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity
113 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec
116 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw
117 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap
120 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept
122 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre
123 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec
125 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu
132 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g
136 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo
137 efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l
139 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation
141 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen
142 More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id
144 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with
147 a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of
148 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial
149 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a
150 resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin
152 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect
153 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru
155 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream
157 this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma memb
158 expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re
159 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept
160 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu
161 omerize with several other tagged receptors (thrombopoietin receptor, transforming growth factor beta
163 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or
166 immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi
171 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy
172 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media
174 forms of the c-Mpl ligand--recombinant human thrombopoietin (rhTPO) and pegylated recombinant human m
176 les exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture.
177 to 10 mum ABA does not increase recombinant thrombopoietin (rTpo)-dependent Mk differentiation or pl
179 karyocytes to the endosteal niche depends on thrombopoietin signaling through the c-MPL receptor on m
180 ressed in hematopoietic cells and suppresses thrombopoietin signaling via its receptor myeloprolifera
183 + thrombopoietin) or four cytokines (Flt3L + thrombopoietin + stem cell factor + interleukin 3).
184 oncontact HUBEC cultures and the addition of thrombopoietin, stem cell factor (SCF), and macrophage c
185 /mpl, silencing of TRIB3 increased basal and thrombopoietin-stimulated megakaryocyte antigen expressi
187 itro to produce proplatelets, independent of thrombopoietin stimulation, and they responded to stimul
189 -Mpl, the cellular receptor for the cytokine thrombopoietin, suggest that c-Mpl does not control HSC
191 of platelet-biased HSCs crucially depends on thrombopoietin, the primary extrinsic regulator of plate
192 de, with the cloning and characterization of thrombopoietin, the primary regulator of this process.
195 ets collected from healthy donors undergoing thrombopoietin therapy were safe and resulted in signifi
197 the hereditary thrombocytosis induced by the thrombopoietin (THPO) receptor MPL P106L mutant remain u
200 ne, MPL, a homodimeric receptor activated by thrombopoietin (THPO), is mutated in myeloproliferative
201 ealed that Bcl-xL expression is regulated by thrombopoietin (THPO)/MPL-signaling induced by AE expres
202 ng identified mutations in the gene encoding thrombopoietin (THPO): THPO R99W, homozygous in affected
203 fied a novel homozygous missense mutation in thrombopoietin (THPO, c.112C>T) in both affected sibling
204 granules, and forming PPTs without exogenous thrombopoietin, thus identifying a novel and unexplored
207 kt in BaF3/Mpl cells restored the ability of thrombopoietin to promote cell cycling in the presence o
210 karyocyte production, signaling initiated by thrombopoietin (TPO) activation of its receptor, myelopr
211 that c-Cbl(-/-) HSCs are hyperresponsive to thrombopoietin (TPO) and display elevated levels of STAT
213 We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patient
214 ulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RA
216 Multiple lines of evidence indicate that thrombopoietin (TPO) contributes to the development of h
218 In our previous studies we demonstrated that thrombopoietin (TPO) enhances levels of HOXB4 mRNA in pr
220 ition, BM from Cib1(-/-) mice, cultured with thrombopoietin (TPO) for 24 hours, produced more highly
221 vels are controlled by circulating levels of thrombopoietin (TPO) functioning to activate megakaryocy
222 etiology of this disease, we identified the thrombopoietin (Tpo) gene as a target of the SMRT-retino
230 ets to the AMR induces hepatic expression of thrombopoietin (TPO) mRNA and protein, thereby regulatin
232 L), increased cell surface expression of the thrombopoietin (TPO) receptor (c-MPL) and enhanced proli
234 ut not CALRdelex9, specifically activate the thrombopoietin (TPO) receptor (MPL) to induce constituti
235 mbocythemia (ET) with mutations in JAK2, the thrombopoietin (TPO) receptor (MPL), and the calreticuli
237 pression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoi
240 on of these cells in the presence of dox and thrombopoietin (TPO) resulted in an exponential (at leas
241 elinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signaling and therefore differentia
242 This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target
244 Multiple lines of evidence indicate that thrombopoietin (TPO) substantially impacts the number of
248 opoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the developme
250 IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of
254 in transcription factors, in the response to thrombopoietin (Tpo), and newly described developmentall
257 using low levels of stem cell factor (SCF), thrombopoietin (TPO), insulin-like growth factor 2 (IGF-
258 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor
259 some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human megaka
260 ) messenger RNA (mRNA) expression; (3) serum thrombopoietin (Tpo), stem cell factor (SCF), interleuki
267 one marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production.
268 ffect of an Src kinase inhibitor, SU6656, on thrombopoietin (TPO)-induced growth and differentiation.
272 s (HSCs) harboring DNA damage are rescued by thrombopoietin (TPO)-mediated DNA repair.1 It has been r
276 induction of a luciferase reporter gene in a thrombopoietin (TPO)-responsive cell line resulted in th
278 reaction of purified mouse MKs isolated from thrombopoietin (TPO)-treated bone marrow (BM) cultures i
288 mbopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human meg
289 F], insulinlike growth factor-1 [IGF-1], and thrombopoietin [TPO]); cytokines (tumor necrosis factor-
290 structed by either in vivo overexpression of thrombopoietin (TPOhigh mice) or megakaryocyte lineage r
291 e 2 (JAK2) is essential for signaling by the thrombopoietin (TpoR) and erythropoietin (EpoR) receptor
292 oped with the discovery that the recombinant thrombopoietins (TPOs) could enhance platelet production
293 tion of VEGFR-3 increased platelet counts in thrombopoietin-treated mice significantly and modulated
294 giopoietin-like 3 and IGF2, but also SCF and thrombopoietin, two other growth factors important for H
295 d; and the primary regulator of the process, thrombopoietin, was cloned and characterized and therape
296 Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in pat
299 ing and have lost the potentiating effect of thrombopoietin (which couples to JAK2) on this pathway.
300 on hepatocytes to enhance the production of thrombopoietin, which in turn interacts with its cognate
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。